Veru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin DRS New Drug Application
Tweet Send to a Friend
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on urology and oncology, announced that the U.S. Food and Drug Administration ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE